Biomarin Pharmaceutical Q3 Adj $0.46 Beats $0.22 Estimate, Sales $581.33M Miss $608.68M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biomarin Pharmaceutical reported Q3 earnings of $0.46 per share, beating the analyst consensus estimate of $0.22 by 109.09%. This is a significant increase from losses of $(0.04) per share from the same period last year. However, the company's quarterly sales of $581.33 million missed the analyst consensus estimate of $608.68 million by 4.49%.
November 01, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biomarin Pharmaceutical's Q3 earnings beat estimates, but sales missed expectations. This mixed result could lead to uncertainty in the stock's short-term performance.
Biomarin's earnings beat estimates, which is a positive signal for the stock. However, the company's sales missed estimates, which could negatively impact the stock. The mixed results create uncertainty, which could lead to volatility in the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100